G01N 33/57449(20130101), G01N 33/57484(20130101), G01N 2800/52(20130101)
The phosphorylation status of the BAD protein is a determinant of ovarian cancer cell responsiveness to platinum chemotherapy. Indirect manipulation of BAD phosphorylation status influences cisplatin sensitivity. BAD phosphorylation represents a biomarker that predicts platinum sensitivity and is a therapeutic target to increase platinum sensitivity. The methods employ phospho-specific antibody against a particular amino acid residue or site. Phospho-specific protein characterization methods include immunohistochemical (IHC), flow cytometric, immunofluorescent, capture-and-detection, or reversed phase assay.
Lancaster, Johnathan; Marchion, Douglas C.; and Chen, Dung-Tsa, "Cancer platinum resistance detection and sensitization method" (2015). USF Patents. 34.
University of South Florida